Cancer therapy and cardiovascular risk: focus on bevacizumab
Panagiota Economopoulou, Athanasios Kotsakis, Ioannis Kapiris, and Nikolaos Kentepozidis
Cancer Manag Res. 2015 Jun 3;7:133-43. doi: 10.2147/CMAR.S77400. eCollection 2015.
CARDIONCOLOGY.ORG ABSTRACT:
Treatment related cardiotoxicity has become an essential part of routine cancer care.
Despite its efficacy, bevacizumab, as other cancer drug therapies, has been associated with significant risk of cardiovascular complications.
© All rights reserved
image source: http://reportherald.com/2019/08/22/global-bevacizumab-market-recent-study-including-business-growth-development-factors-and-growth-analysis-2019-2024/